[A Case of Aggressive Angiomyxoma Completely Resected with Organ Preservation by Preoperative Hormone Therapy].
Kambe. Masato M; Sato. Sumito S; Tatsumi. Makoto M; Kinjo. Tatsuya T; Hamano. Takashi T; Kobayashi. Yasuyuki Y
Key Findings
- Leuprorelin (GnRH agonist) reduced tumor volume from 20×13 cm to 10×7.5 cm over 12 doses.
- Side effects such as fatigue and nausea were reported during therapy.
- Further tumor shrinkage plateaued after the initial reduction, requiring surgical removal.
- Pre‑operative hormone therapy enabled organ‑preserving surgery for a rare pelvic tumor.
Practical Outcomes
- GnRH agonists can shrink certain hormone‑responsive pelvic tumors before surgery, but the benefit is limited and comes with side effects. This approach is specific to rare tumor cases and isn’t a general health or longevity strategy for most people.
Summary
In a 34‑year‑old woman with a rare pelvic tumor called aggressive angiomyxoma, a hormone drug (leuprorelin, a GnRH agonist) was given for 16 months. The tumor shrank about half in size, which helped surgeons remove it completely while saving her organs, but the drug caused fatigue and nausea and stopped making the tumor smaller after the first few months.
Abstract
A 34‒year‒old woman presented with a pelvic tumor in the Douglas pouch during her first pregnancy, initially suspected to be a desmoid tumor and managed subsequently. Biopsy during cesarean section in her second pregnancy confirmed aggressive angiomyxoma (AAM). Postpartum tumor growth prompted a 16‒month course of gonadotropin‒releasing hormone agonist therapy (leuprorelin acetate, 1.88 mg every 4 weeks), which reduced tumor size from 20×13 cm to 10×7.5 cm after 12 doses. However, adverse effects, such as fatigue and nausea occurred, and further tumor shrinkage was minimal, necessitating surgical intervention. A left posterior sacral approach allowed complete tumor resection while preserving the rectum, reproductive organs, and autonomic nerves. AAM is a rare tumor of the pelvis or external genitalia in young women. Although surgical excision remains the primary treatment, no standardized approach exists. This case demonstrates the role of preoperative hormone therapy in significantly reducing tumor size, thereby facilitating complete excision with organ preservation, and underscore its potential role in AAM management.
Study Information
pubmed
2025